## 2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

## Claims 1-11 (Cancelled)

- Claim 12. (Withdrawn) A method of preparing a dendritic cell population comprising the steps of:
  - (a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;
  - (b) transfecting the dendritic cells with a gene encoding an antigen; and
  - (c) allowing the dendritic cells to process and express the antigen.
- Claim 13. (Withdrawn) A method according to claim 12, further comprising contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- $\alpha$ , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.

## Claim 14 (Cancelled)

- Claim 15 (Previously presented) A method of preparing a dendritic cell population comprising the steps of:
  - (a) contacting hematopoietic stem or progenitor cells with a growth factor or cytokine, wherein the growth factor or cytokine consists of flt3-ligand in an amount sufficient to generate a dendritic cell population;
  - (b) exposing the dendritic cells to an antigen; and
  - (c) allowing the dendritic cells to process and express the antigen.
- Claim 16 (Currently amended) The method according to claim 15, wherein the growth factor or cytokine consists of fl3 ligand and GM-CSF.
- A method of preparing a dendritic cell population comprising the steps of:
  - (a) contacting hematopoietic stem or progenitor cells with a growth factor or cytokine, wherein the growth factor or cytokine consists of flt3-ligand and GM-CSF in amounts sufficient to generate a dendritic cell population;
  - (b) exposing the dendritic cells to an antigen; and
  - (c) allowing the dendritic cells to process and express the antigen.

Claim 17 (Withdrawn) The method according to claim 12 wherein the flt3-ligand is a recombinant human flt3-ligand.

Claim 18. (Withdrawn) The method according to claim 13 wherein the flt3-ligand is a recombinant human flt3-ligand.

Claim 19. (Withdrawn) The method according to claim 13 wherein the molecule is a recombinant human GM-CSF.

Claim 20. (Withdrawn) The method according to claim 13 wherein the molecule is CD40 ligand.

Claim 21. (Withdrawn) The method according to claim 13 wherein the molecule is c-kit ligand.

Claim 22. (Withdrawn) The method according to claim 13 wherein the molecule is TNF-a.

Claim 23 (Previously presented) The method according to claim 15 wherein the flt3-ligand is human flt3-ligand.

Claim 24 (Previously presented) The method according to claim 16 wherein the flt3-ligand is human flt3-ligand.

Claim 25 (Previously presented) The method according to claim 16 wherein the GM-CSF is human GM-CSF.

Claim 26. (Withdrawn) The method according to claim 16 wherein the molecule is CD40 ligand.

Claim 27. (Withdrawn) The method according to claim 16 wherein the molecule is c-kit ligand.

Claim 28. (Withdrawn) The method according to claim 16 wherein the molecule is TNF- $\alpha$ .

Claim 29 (Previously presented) A method of preparing a dendritic cell population, the method comprising contacting in vitro hematopoietic stem or

progenitor cells with a growth factor or cytokine, wherein the growth factor or cytokine consists of flt3-ligand in an amount sufficient to generate a dendritic cell population, thereby generating the dendritic cell population.

Claim 30 (Canceled) The method of claim 29, wherein the hematopoietic stem or progenitor cells have been enriched for the CD34+ phenotype.

Claim 31 (Currently amended) The method-of claim 29, wherein the growth factor or cytokine consists of fl3-ligand and GM CSF.

A method of preparing a dendritic cell population, the method comprising contacting in vitro hematopoietic stem or progenitor cells with a growth factor or cytokine, wherein the growth factor or cytokine consists of flt3-ligand and GM-CSF in amounts sufficient to generate a dendritic cell population, thereby generating the dendritic cell population.

Claim 32 (Previously presented) The method of claim 31, wherein the GM-CSF is human GM-CSF.

Claim 33. (Withdrawn) The method of claim 31, wherein the molecule is TNF-a.

Claim 34. (Withdrawn) The method of claim 31, wherein the molecule is c-kit ligand.

Claim 35. (Withdrawn) The method of claim 31, wherein the molecule is CD40 ligand.

Claim 36 (Previously presented) The method according to claim 29 wherein the flt3-ligand is human flt3-ligand.

Claim 37 (New) The method according to claim 31, wherein the flt3-ligand is human flt3-ligand.

Claim 38 (New) The method of claims 15, 16, 29, and 31, wherein the hematopoietic stem or progenitor cells have been enriched for the CD34+ phenotype.